Antimüllerian hormone levels are not affected by duration of contraception use in reproductive-age women
Oct 17, 2020
Origin: ASRM Press Release
Washington, D.C.—It is known that antimüllerian hormone (AMH) levels in women who use contraceptives are lower. However, a study presented at the 2020 Scientific Congress by Modern Fertility’s Head of Clinical Research, Dr. Sharon Briggs shows that the duration of contraceptive use is not associated with any additional variation in AMH levels in women during their reproductive years.
AMH levels are indicative of a woman’s ovarian reserve. Higher AMH values (greater than 1 ng/mL) usually signify that a woman has a normal ovarian reserve and lower numbers (less than 1 ng/mL) may indicate a low or diminished ovarian reserve.
The study included 2,358 participants who used an at-home fertility hormone test between June 2018 and April 2020. Women were between ages 21-46 and were using either the levonorgestrel IUD (LNG-IUD), implant, combined oral contraceptive (COC), or vaginal ring. The duration of contraceptive use was self-reported and ranged from one to three months up to more than 20 years. Researchers observed no impact of either long or short term usage on AMH levels for any of the contraceptive methods included in this study.
“The results of this study should be reassuring to women who have been on hormonal contraception but are now interested in building their families. Neither long, nor short term contraceptive use really impacts AMH levels,” said Eve Feinberg, MD President of the Society for Reproductive Endocrinology and Infertility.